Staten Island, NY, United States of America

Concetta Freund

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ptc Therapeutics, Inc.. Active years: 2011.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovator Spotlight: Concetta Freund**

Introduction

Concetta Freund, an accomplished inventor based in Staten Island, NY, has made significant contributions to the field of medicine, particularly in the treatment of viral infections. With a strong focus on innovative therapies, she holds a patent that addresses the pressing need for effective treatments for Hepatitis C.

Latest Patents

Her noteworthy patent, titled "Methods for Treating Hepatitis C," embodies the discovery of compounds that inhibit the replication of the Hepatitis C Virus (HCV). This invention outlines methods for using these compounds in the treatment and prevention of HCV infection, showcasing her commitment to advancing healthcare solutions.

Career Highlights

Concetta currently works at PTC Therapeutics, Inc., a company known for its dedication to transforming the lives of patients with serious diseases through innovative medicines. Her work is pivotal in the ongoing efforts to combat viral infections, reflecting her expertise and dedication to medical research.

Collaborations

Throughout her career, Concetta has collaborated with esteemed colleagues such as Gary Mitchell Karp and Peter Seongwoo Hwang. These partnerships have played a crucial role in her research and the development of her patented methods, emphasizing the importance of teamwork within the scientific community.

Conclusion

Concetta Freund's contributions to virology and her innovative approaches to treating Hepatitis C not only highlight her expertise as an inventor but also demonstrate her commitment to improving global health. As she continues her work at PTC Therapeutics, her findings may pave the way for new therapeutic avenues that can better serve patients affected by this challenging infection.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…